High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease

Yeh, Edward T.H.

doi:10.1002/clc.4960280905

Cited by 72 publications

(57 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study indeed demonstrated that pioglitazone-induced increase in adiponectin was associated with a significant decrease in hsCRP, which has been implicated in a valuable marker for atherosclerosis [21][22][23]. This anti-inflammatory effect may play a crucial role in preventing the development of atherosclerosis and cardiovascular disease.…”

Section: Discussionsupporting

confidence: 72%

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Fujitaka

Otani

et al. 2011

Endocr J

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is characterized by accumulation of visceral fat associated with the clustering of metabolic and pathophysiological cardiovascular risk factors; impaired glucose tolerance or type-2 diabetes mellitus (T2DM), dyslipidemia and hypertension [1], and has a strong impact on the global incidence of the life-threatening cardiovascular disease such as stroke and myocardial infarction [2,3]. The prevalence of MetS is rapidly increasing worldwide not only in industrialized countries but also in developing countries associated with a change in the lifestyle including the increase in food intake and the decrease abstract. Type 2 diabetes mellitus (T2DM) associated with metabolic syndrome (MetS) represents a high risk of cardiovascular disease. We compared the effect of early intervention with pioglitazone versus voglibose on physical and metabolic profiles and serum adiponectin level in patients with T2DM associated with MetS. Sixty patients who were diagnosed for the first time as T2DM associated with MetS were analyzed for insulin sensitivity, lipid profile, serum adiponectin and systemic inflammation. Those patients were randomly assigned to oral pioglitazone group (n = 30) or voglibose group (n = 30) in addition to conventional diet and exercise training. Body mass index and waist circumference did not change in the pioglitazone group, whereas these physical parameters significantly decreased in the voglibose group during a 6-month follow-up period. However, glycosylated hemoglobin, fasting plasma glucose, and HOMA-IR more significantly decreased in the pioglitazone group. The level of serum adiponectin especially high-molecular weight adiponectin markedly increased in the pioglitazone group. Moreover, high sensitive CRP significantly decreased only in the pioglitazone group. These results suggest that voglibose is superior in improving obesity, while pioglitazone is superior in ameliorating insulin sensitivity and increasing serum adiponectin in patients with an early stage of T2DM associated with MetS.

show abstract

Section: Discussionsupporting

confidence: 72%

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Fujitaka

Otani

et al. 2011

Endocr J

View full text Add to dashboard Cite

show abstract

“…When measured with new high-sensitivity assays, the levels of CRP have proven to predict future cardiovascular risk. Among apparently healthy men and women, the levels of high-sensitivity-CRP (hs-CRP) of !1, 1-3 and O3 mg/l distinguish between those at low, moderate and high risk of future cardiovascular disease (4).…”

Section: Introductionmentioning

confidence: 99%

High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents.

Soriano‐Guillén

Hernández-García

Pita³

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: We intend to assess the utility of the high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular risk in obese children and adolescents. Methods: The study included children and adolescents between 6 and 18 years of age with a body mass index (BMI) higher than 2 SDS. All the patients had their blood pressure taken and hs-CRP, hepatic function, lipid profile and uric acid were determined after 12 h of fasting. Likewise, an oral glucose tolerance test was performed, determining basal glucose and insulin levels, and after stimulus. We considered the presence of metabolic syndrome when the obese children and teenagers showed at least two of the following conditions: decreased high density lipoprotein (HDL)-cholesterol, hypertriglyceridemia, hypertension or alteration in glucose metabolism. Results: Out of the 115 obese children studied, 24% showed signs of metabolic syndrome. Those with metabolic syndrome presented higher levels of hs-CRP (mean: 3.8 mg/l; 95% CI: 2.8-4.8) in comparison with the obese patients who did not show signs of metabolic syndrome (mean: 2 mg/l; 95% CI: 1.5-2.5). After a multivariate analysis, the variables that appear to influence the changes in hs-CRP were BMI, triglycerides and HDL-cholesterol levels. Conclusion: The hs-CRP is a useful tool for early diagnosis of cardiovascular risk in obese children and teenagers.European Journal of Endocrinology 159 R1-R4

show abstract

“…12,13 Evidence also implicates CRP, and thus inflammation, as a useful clinical measure for identifying risk of developing the insulin resistance syndrome, particularly in women. 14,15 Serum CRP concentrations correlate positively with abdominal obesity, hyperinsulinemia, and other components of the insulin resistance syndrome. Nevertheless, associations of CRP with insulin resistance independent of obesity suggest that divergent pathways linking inflammation and insulin resistance are of importance, especially among nonobese individuals.…”

mentioning

confidence: 99%

C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy

et al. 2008

View full text Add to dashboard Cite

Abstract-Women with a history of preeclampsia or eclampsia (seizure during preeclamptic pregnancy) are at increased risk for cardiovascular disease after pregnancy for reasons that remain unclear. Prospective studies during pregnancy suggest that inflammation, dyslipidemia, and insulin resistance are associated with increased risk of preeclampsia. Elevated serum C-reactive protein (CRP Ͼ3 mg/L) is an indicator of inflammation and cardiovascular risk. We hypothesized that Icelandic postmenopausal women with a history of eclampsia would manifest higher concentrations of serum CRP than Icelandic postmenopausal controls with a history of uncomplicated pregnancies. We also asked whether elevated CRP is associated with the dyslipidemia and insulin resistance previously identified in this cohort. CRP, measured by high-sensitivity enzyme-linked immunoassay, was higher in women with prior eclampsia (nϭ25) than controls (nϭ28)

show abstract

High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease

Cited by 72 publications

References 38 publications

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents.

C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy

Contact Info

Product

Resources

About